Evan Seigerman
Stock Analyst at BMO Capital
(3.83)
# 704
Out of 5,005 analysts
146
Total ratings
53.12%
Success rate
8.94%
Average return
Main Sectors:
Stocks Rated by Evan Seigerman
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| VRTX Vertex Pharmaceuticals | Maintains: Outperform | $557 → $530 | $403.30 | +31.42% | 16 | Aug 5, 2025 | |
| INCY Incyte | Maintains: Underperform | $52 → $60 | $86.85 | -30.92% | 13 | Jul 30, 2025 | |
| IRON Disc Medicine | Maintains: Outperform | $112 → $120 | $67.78 | +77.04% | 6 | May 12, 2025 | |
| NBIX Neurocrine Biosciences | Maintains: Market Perform | $96 → $115 | $137.03 | -16.08% | 15 | May 6, 2025 | |
| GILD Gilead Sciences | Maintains: Outperform | $115 → $120 | $112.69 | +6.49% | 17 | Apr 17, 2025 | |
| BIIB Biogen | Maintains: Market Perform | $156 → $139 | $159.88 | -13.06% | 27 | Feb 13, 2025 | |
| BMY Bristol-Myers Squibb Company | Maintains: Market Perform | $57 → $61 | $45.45 | +34.21% | 11 | Nov 12, 2024 | |
| LLY Eli Lilly and Company | Maintains: Outperform | $1,001 → $1,101 | $839.87 | +31.09% | 8 | Aug 9, 2024 | |
| GPCR Structure Therapeutics | Initiates: Outperform | $40 | $27.28 | +46.63% | 1 | Feb 28, 2023 | |
| REPL Replimune Group | Maintains: Outperform | $30 → $40 | $4.73 | +745.67% | 1 | Oct 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $757 → $788 | $600.00 | +31.33% | 17 | Aug 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $8 → $2.5 | $3.71 | -32.61% | 2 | Aug 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $263 → $243 | $297.89 | -18.43% | 6 | Apr 28, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $18 → $12 | $5.56 | +115.83% | 2 | Mar 31, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $60 | $27.37 | +119.22% | 1 | Nov 19, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $13 → $30 | $1.78 | +1,585.39% | 3 | May 12, 2020 |
Vertex Pharmaceuticals
Aug 5, 2025
Maintains: Outperform
Price Target: $557 → $530
Current: $403.30
Upside: +31.42%
Incyte
Jul 30, 2025
Maintains: Underperform
Price Target: $52 → $60
Current: $86.85
Upside: -30.92%
Disc Medicine
May 12, 2025
Maintains: Outperform
Price Target: $112 → $120
Current: $67.78
Upside: +77.04%
Neurocrine Biosciences
May 6, 2025
Maintains: Market Perform
Price Target: $96 → $115
Current: $137.03
Upside: -16.08%
Gilead Sciences
Apr 17, 2025
Maintains: Outperform
Price Target: $115 → $120
Current: $112.69
Upside: +6.49%
Biogen
Feb 13, 2025
Maintains: Market Perform
Price Target: $156 → $139
Current: $159.88
Upside: -13.06%
Bristol-Myers Squibb Company
Nov 12, 2024
Maintains: Market Perform
Price Target: $57 → $61
Current: $45.45
Upside: +34.21%
Eli Lilly and Company
Aug 9, 2024
Maintains: Outperform
Price Target: $1,001 → $1,101
Current: $839.87
Upside: +31.09%
Structure Therapeutics
Feb 28, 2023
Initiates: Outperform
Price Target: $40
Current: $27.28
Upside: +46.63%
Replimune Group
Oct 14, 2022
Maintains: Outperform
Price Target: $30 → $40
Current: $4.73
Upside: +745.67%
Aug 4, 2022
Maintains: Outperform
Price Target: $757 → $788
Current: $600.00
Upside: +31.33%
Aug 2, 2022
Downgrades: Market Perform
Price Target: $8 → $2.5
Current: $3.71
Upside: -32.61%
Apr 28, 2022
Maintains: Market Perform
Price Target: $263 → $243
Current: $297.89
Upside: -18.43%
Mar 31, 2022
Maintains: Outperform
Price Target: $18 → $12
Current: $5.56
Upside: +115.83%
Nov 19, 2021
Initiates: Outperform
Price Target: $60
Current: $27.37
Upside: +119.22%
May 12, 2020
Maintains: Outperform
Price Target: $13 → $30
Current: $1.78
Upside: +1,585.39%